Nath Bio-Genes (India) Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Satish Kagliwal
Chief executive officer
₹6.6m
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 25.5yrs |
| CEO ownership | n/a |
| Management average tenure | 6.6yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Is Nath Bio-Genes (India) (NSE:NATHBIOGEN) A Risky Investment?
Dec 03
Here's Why Shareholders Should Examine Nath Bio-Genes (India) Limited's (NSE:NATHBIOGEN) CEO Compensation Package More Closely
Aug 11Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) Solid Earnings May Rest On Weak Foundations
Jul 31Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN) Shares Fly 34% But Investors Aren't Buying For Growth
Jul 02These 4 Measures Indicate That Nath Bio-Genes (India) (NSE:NATHBIOGEN) Is Using Debt Reasonably Well
Jun 27Nath Bio-Genes (India) (NSE:NATHBIOGEN) Has More To Do To Multiply In Value Going Forward
Apr 05Returns On Capital At Nath Bio-Genes (India) (NSE:NATHBIOGEN) Have Hit The Brakes
Oct 24Nath Bio-Genes (India) (NSE:NATHBIOGEN) Seems To Use Debt Quite Sensibly
Aug 05Nath Bio-Genes (India) (NSE:NATHBIOGEN) Has Some Way To Go To Become A Multi-Bagger
Jun 07Some Investors May Be Worried About Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) Returns On Capital
Feb 11We Think Nath Bio-Genes (India) (NSE:NATHBIOGEN) Is Taking Some Risk With Its Debt
Aug 27Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) Returns On Capital Not Reflecting Well On The Business
Jun 19Nath Bio-Genes (India) (NSE:NATHBIOGEN) Has A Pretty Healthy Balance Sheet
Feb 24Returns On Capital Signal Tricky Times Ahead For Nath Bio-Genes (India) (NSE:NATHBIOGEN)
May 27Is Nath Bio-Genes (India) (NSE:NATHBIOGEN) A Risky Investment?
Feb 28The Trends At Nath Bio-Genes (India) (NSE:NATHBIOGEN) That You Should Know About
Feb 07Declining Stock and Decent Financials: Is The Market Wrong About Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN)?
Jan 19The Nath Bio-Genes (India) (NSE:NATHBIOGEN) Share Price Is Up 149% And Shareholders Are Boasting About It
Jan 01Why Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) CEO Pay Matters
Dec 14
These 4 Measures Indicate That Nath Bio-Genes (India) (NSE:NATHBIOGEN) Is Using Debt Reasonably Well
Nov 26Here's What To Make Of Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) Returns On Capital
Nov 05Do Its Financials Have Any Role To Play In Driving Nath Bio-Genes (India) Limited's (NSE:NATHBIOGEN) Stock Up Recently?
Oct 15Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN) Might Not Be As Mispriced As It Looks After Plunging 25%
Sep 24Many Still Looking Away From Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN)
Sep 08Introducing Nath Bio-Genes (India) (NSE:NATHBIOGEN), The Stock That Soared 311% In The Last Five Years
Sep 07Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN) Doing What It Can To Lift Shares
Aug 18Here's What We Think About Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) CEO Pay
Jul 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | n/a | n/a | ₹407m |
| Sep 30 2024 | n/a | n/a | ₹394m |
| Jun 30 2024 | n/a | n/a | ₹398m |
| Mar 31 2024 | ₹7m | ₹7m | ₹396m |
| Dec 31 2023 | n/a | n/a | ₹374m |
| Sep 30 2023 | n/a | n/a | ₹379m |
| Jun 30 2023 | n/a | n/a | ₹374m |
| Mar 31 2023 | ₹5m | ₹5m | ₹350m |
| Dec 31 2022 | n/a | n/a | -₹827m |
| Sep 30 2022 | n/a | n/a | -₹813m |
| Jun 30 2022 | n/a | n/a | -₹815m |
| Mar 31 2022 | ₹5m | ₹5m | -₹674m |
| Dec 31 2021 | n/a | n/a | ₹561m |
| Sep 30 2021 | n/a | n/a | ₹575m |
| Jun 30 2021 | n/a | n/a | ₹593m |
| Mar 31 2021 | ₹5m | ₹5m | ₹557m |
| Dec 31 2020 | n/a | n/a | ₹562m |
| Sep 30 2020 | n/a | n/a | ₹558m |
| Jun 30 2020 | n/a | n/a | ₹565m |
| Mar 31 2020 | ₹5m | ₹5m | ₹505m |
| Dec 31 2019 | n/a | n/a | ₹482m |
| Sep 30 2019 | n/a | n/a | ₹478m |
| Jun 30 2019 | n/a | n/a | ₹477m |
| Mar 31 2019 | ₹5m | ₹5m | ₹384m |
| Dec 31 2018 | n/a | n/a | ₹349m |
| Sep 30 2018 | n/a | n/a | ₹353m |
| Jun 30 2018 | n/a | n/a | ₹353m |
| Mar 31 2018 | ₹3m | ₹3m | ₹294m |
Compensation vs Market: Satish's total compensation ($USD76.16K) is above average for companies of similar size in the Indian market ($USD41.54K).
Compensation vs Earnings: Satish's compensation has increased by more than 20% in the past year.
CEO
Satish Kagliwal (67 yo)
25.5yrs
Tenure
₹6,600,000
Compensation
Mr. Satish Kagliwal serves as the Chairman of the Board at Agri-tech (India) Limited and has been its Executive Director since August 30, 1999 & serves as it's Managing Director of Agri-tech (India) Limite...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Executive Director | no data | ₹6.60m | no data | |
| Company Secretary & Compliance Officer | 6.6yrs | ₹844.00k | no data | |
| Vice President of Marketing | no data | ₹7.99m | no data | |
| Executive Director | no data | ₹20.00k | 0.0015% ₹ 51.1k | |
| Chief People Officer | no data | ₹4.14m | no data | |
| Vice President of R&D | 6.7yrs | ₹10.07m | no data | |
| Chief Financial Officer | less than a year | no data | no data |
6.6yrs
Average Tenure
58yo
Average Age
Experienced Management: NATHBIOGEN's management team is seasoned and experienced (6.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Executive Director | 25.5yrs | ₹6.60m | no data | |
| Executive Director | 5.8yrs | ₹20.00k | 0.0015% ₹ 51.1k | |
| Non-Executive Director | 1.8yrs | ₹15.00k | no data | |
| Independent Non-Executive Director | 2.9yrs | ₹20.00k | no data | |
| Independent Non-Executive Director | 4.3yrs | ₹20.00k | no data | |
| Independent Non-Executive Director | 4.3yrs | ₹23.00k | no data | |
| Independent Non-Executive Director | 4yrs | ₹23.00k | no data |
4.3yrs
Average Tenure
64yo
Average Age
Experienced Board: NATHBIOGEN's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 20:30 |
| End of Day Share Price | 2025/02/01 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nath Bio-Genes (India) Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kameswari V. S. Chavali | FirstCall Research |